Cytokinetics Stock Surges on Promising Phase 2 Trial Results
Cytokinetics Inc’s stock (CYTK: NSD) surged by over 30% after positive Phase 2 trial results of its lead drug candidate, omecamtiv mecarbil,…
Browse research
Tag: Earnings
General Motors Stock Faces Decline amid Emerging Challenges
General Motors (GM: NYE) experienced a decline in its stock price after the emergence of various issues. Investors are worried about how…
Analysts Rates Esports Entertainment Group Inc. as a Consensus “Neutral” Rating
GMBL Stock Analysis Esports Entertainment Group Inc’s stock analysis indicates a slightly bearish outlook, driven by three positive signals and five negative…
Wedbush Boosts price target for Tesla from $310 to $350
Analyst Ratings Coverage: TSLA In a recent statement on Dec 21st at 6:21pm, Wedbush analyst Dan Ives announced an upward revision of…
Stock News & Ratings Roundup for December 22nd
Top Stock News Fed Rate Cuts in 2024 Despite Shift in Rate-Setter Composition: The annual rotation of members on the U.S. Federal…